-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress
Review
(2909) Views (1413) Full article downloads
Authors: Jacob George, Allan D Struthers
Published Date March 2009
Volume 2009:5 Pages 265 - 272
DOI: http://dx.doi.org/10.2147/VHRM.S4265
Jacob George, Allan D Struthers
Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
Abstract: Oxidative stress plays an important role in the progression of vascular endothelial dysfunction. The two major systems generating vascular oxidative stress are the NADPH oxidase and the xanthine oxidase pathways. Allopurinol, a xanthine oxidase inhibitor, has been in clinical use for over 40 years in the treatment of chronic gout. Allopurinol has also been shown to improve endothelial dysfunction, reduce oxidative stress burden and improve myocardial efficiency by reducing oxygen consumption in smaller mechanistic studies involving various cohorts at risk of cardiovascular events. This article aims to explain the role of xanthine oxidase in vascular oxidative stress and to explore the mechanisms by which allopurinol is thought to improve vascular and myocardial indices.
Keywords: allopurinol, vascular oxidative stress, vascular endothelial dysfunction
Other articles by Dr Jacob George
Readers of this article also read:
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Management of hyperuricemia in gout: focus on febuxostat
Gout disease-specific quality of life and the association with gout characteristics
New advances in the treatment of gout: review of pegloticase
New and improved strategies for the treatment of gout
Survival of women with breast cancer in central and northern Denmark, 1998–2009
Erratum
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




